Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Whole Genome Sequencing Application Developed for Mutation Discovery

By LabMedica International staff writers
Posted on 28 May 2009
Investigators have developed a "whole-genome sequencing approach” to mapping mutations in fruit flies. More...
The innovative methodology has the potential to reduce the time and effort required to identify mutations of biologic interest.

The researchers, from the Stowers Institute of Medical Research's (Kansas City, KS, USA) Hawley Lab and Molecular Biology Facility, mapped a fruit-fly mutation caused by the compound ethyl methanesulfonate (EMS) by determining the DNA sequence of the mutant fly's genome. The study's findings provide clues into the process of EMS mutagenesis and into gene conversion events involving balancer chromosomes--genetic tools used to prevent genetic recombination between homologous chromosomes during meiosis.

Model organisms such as fruit flies are used in research for studying both normal biologic mechanisms and human disease. Fruit fly genes can be inserted, deleted, or modified, and large numbers of flies can be randomly mutated to generate interesting phenotypes relevant to human disease. Finding the mutated gene responsible for a specific phenotype is labor-intensive and time-consuming, and many mutations that cause medically relevant phenotypes are not discovered. The new approach lowers the problem of finding mutations and greatly accelerates the discovery of genes important for human health.

"This approach will change the way fruit fly genetics is done,” said Scott Hawley, Ph.D., Investigator and coequal senior author of the study. "Traditional mapping approaches to identify mutations are inefficient procedures. Our whole-genome sequencing approach is fast and cost-effective. Among other potential uses, it also carries the potential to pinpoint inheritable molecular characteristics that are controlled by several genes at once.”

"The traditional mapping method could take months to years depending on the complexity of the phenotype,” said Karen Staehling-Hampton, Ph.D., managing director of molecular biology and coequal senior author of the research. "This advance will allow us to map mutations of interest in just a few weeks. The next-generation sequencing technology used for this project is extremely exciting. It will allow researchers to sequence genomes for a few thousand dollars, a cost unheard of just a few years ago. It will also enable them to take their science in new directions and answer new questions that were not possible with traditional sequencing technology.”

The study was published in the May 2009 issue of the journal Genetics.

Related Links:

Stowers Institute of Medical Research



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.